MAM
FDMT icon

Meeder Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Meeder Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,923
Closed -$22K – 850
2025
Q2 		$22K Buy
+5,923
New +$20.8K ﹤0.01% 501
2025
Q1 		– Sell
-1,394
Closed -$7.76K – 952
2024
Q4 		$7.76K Buy
+1,394
New +$10.9K ﹤0.01% 758

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Meeder Asset Management's FDMT Position: Q3 2025 in Review

Meeder Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 5,923 shares — an estimated $22K sold.

Meeder Asset Management first reported a position in FDMT in Q4 2024 and held it in 2 quarters. The position peaked at $22K in Q2 2025. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • Meeder Asset Management reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Meeder Asset Management sold 5,923 4D Molecular Therapeutics shares in Q3 2025, an estimated $22K.
  • Meeder Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 2 quarters.
  • Meeder Asset Management's 4D Molecular Therapeutics position peaked at $22K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Meeder Asset Management's 13F filing for Q3 2025, filed 24 Oct 2025.